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Biosensors discriminated between urines collected from donors receiving a rabies vaccine (RV) versus controls
Biosensors discriminated between the urine odors of mice treated with lipopolysaccharide (LPS) from the urine of control mice
LPS-trained biosensors could distinguish between the odors of LPS-treated mouse urine and RV-treated mouse urine.
Discriminations by the biosensors were made on the basis of odor alone.
Volatile metabolites arising from immunization may be products of an innate immune response.
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a b s t r a c t
Infections have been shown to alter body odor. Because immune activation accompanies both infection and
immunization, we tested the hypothesis that classical immunization might similarly result in the alteration of
body odors detectable by trained biosensor mice. Using a Y-maze, we trained biosensor mice to distinguish
between urine odors from rabies-vaccinated (RV) and unvaccinated control mice. RV-trained mice generalized
this training to mice immunized with the equine West Nile virus (WNV) vaccine compared with urine of
corresponding controls. These results suggest that there are similarities between body odors of mice immunized
with these two vaccines. This conclusion was reinforced when mice could not be trained to directly discriminate
between urine odors of RV- versus WNV-treated mice. Next, we trained biosensor mice to discriminate the urine
odors of mice treated with lipopolysaccharide (LPS; a general elicitor of innate immunological responses) from
the urine of control mice. These LPS-trained biosensors could distinguish between the odors of LPS-treated
mouse urine and RV-treated mouse urine. Finally, biosensor mice trained to distinguish between the odors of
RV-treated mouse urine and control mouse urine did not generalize this training to discriminate between
the odors of LPS-treated mouse urine and control mouse urine. From these experiments, we conclude that:
(1) immunization alters urine odor in similar ways for RV and WNV immunizations; and (2) immune activation
with LPS also alters urine odor but in ways different from those of RV and WNV.
Published by Elsevier Inc.

1. Introduction
Chemical signals are the primary form of social communication for
many species [1–3]. Although most research has been devoted to
communication of social messages such as sex, age, and individual
identity, volatile odorants may also communicate information about
an animal's health status [4–6]. Odors associated with illness are often
avoided by members of the same species, presumably acting to reduce
the probability of disease spread [7]. Conversely, it might be adaptive
for the infective agent to induce chemosensory changes in the
host that increase both inter- and intraspeciﬁc interactions, thereby
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increasing transmission rates. An example of attraction has been
demonstrated for interspeciﬁc interactions between human hosts and
an insect vector [8].
The mechanisms underlying changes in body odor caused by disease
are poorly understood and the speciﬁcity of odor changes to a speciﬁc
disease has rarely been explored. For some diseases the mechanism
underlying a body odor change is obvious and very non-speciﬁc. For
example, diseases that alter feeding and drinking behavior or gut
function are likely to alter odors associated with waste products such
as urine and feces in non-speciﬁc ways. A more interesting potential
pathway for diseases to alter body odor is via immune function —
which is known to be intimately related to body odor composition
[9–11]. Based on this reasoning, we hypothesized that vaccination
may induce a signiﬁcant alteration of body odor.
To test this hypothesis, we ﬁrst conducted experiments asking
whether immunization with rabies (RV) or West Nile virus (WNV)
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vaccines alters body odors as determined by trained sensor mice in Ymaze odor training paradigm [12]. This behavioral assay is wellequipped to identify differences among various stimuli on the basis of
odor. The Y-maze has successfully been used to demonstrate that rodents can discriminate between many different sources of odor variation, including: fetal odortype [13,14], disease [12,15], age [16], and
diet [17]. We used urine as a representative source of body odor in
these experiments because it is a potent source of mouse body odors
[12,18].
Finding that urine odors were altered by treatment with the vaccines, we next examined whether odor changes are also elicited from
exposure to lipopolysaccharide (LPS), a component of bacterial cell
walls. Treatment with LPS induces a robust pro-inﬂammatory cytokine
response [19] and previous experiments have indicated that body
odors from LPS-treated animals elicit aversive behavioral responses
from conspeciﬁcs [20]. The Y-maze odor training paradigm was used
to evaluate similarities in body odor alterations produced by these different immunogens.
2. Materials and methods
2.1. Subjects
Inbred C57BL/6 mice were used as both biosensors and urine donors
receiving treatments. Three biosensor panels (a unique panel for
each experiment) each consisted of 5–7 individuals of mixed sex
ranging in age from 6 to 14 months (Table 1). Urine donors were
males 7–10 weeks of age at the time of treatment. The number of
donors in each treatment group depended on the number of samples
needed for bioassay trials (Table 1). Treated urine donors were provided
ad libitum access to water and pelleted rations. Biosensors were provided ad libitum feed (Teklad Rodent Diet 8604; Harlan, Madison, WI), but
were restricted from water for 23 h daily. Procedures involving animals
were approved by the Institutional Animal Care and Use Committees of
Monell (#1123) and the United States Department of Agriculture, Animal and Plant Health Inspection Service, Wildlife Services, National
Wildlife Research Center (QA-2021).
2.2. Treatments
The inactivated rabies vaccine RabVac-3® (RV; Fort Dodge Animal
Health, Fort Dodge, IA, USA) was diluted (1:15) in 0.01 M sterile
phosphate-buffered saline (PBS) for i.p. delivery of 300 μL. The live,

Table 1
Overview of trials conducted in a Y-maze with number of donors by treatment and urine
collection days (post-treatment). Rabies (RV) = treatment with RabVac-3® vaccine;
West Nile virus (WNV) = treatment with PreveNile® West Nile virus vaccine; LPS =
treatment with lipopolysaccharide; and control = treatment with phosphate-buffered
saline.
Experiment

Traininga
c

1a

RV vs. control (7)

1b
2a

RV vs. WNV (7)d
LPS vs. control (3)
LPS vs. control (3)

2b
3

LPS vs. control (7)e
RV vs. control (5)

a

Generalizationb

Donors

RV vs. control (validation)
WNV vs. control
WNV vs. RV
None
LPS vs. control (validation)
LPS vs. control (validation)

70 RV
30 control
16 WNV

LPS vs. RV
RV vs. control (validation)
LPS vs. control

40 LPS
20 control
10 RV
21 RV
17 control

Odors associated with treatments in bold were the rewarded choice in training trials.
Identities of stimuli were blind to the operator during generalization trials and were
unrewarded.
c
Number of subjects in the biosensor panel is indicated in parentheses.
d
Experiment 1b donors are the same as Experiment 1a.
e
Experiment 2b donors are derived from Experiment 2a.
b

81

attenuated West Nile virus (WNV) vaccine, PreveNile® (Intervet, Inc.,
Millsoboro, DE, USA) was prepared by dissolving 15 mg of the vaccine
in 100 mL PBS for i.p. delivery of 200 μL. Vaccine dilution rates (based
on relative mass ratios among species of intended vaccine use) resulted
in ~50× reduction of RV dose as indicated for pets and ~1500× reduction of WNV vaccine dose as recommended for horses. The lipopolysaccharide (LPS) solution was prepared in PBS at a concentration of
0.20 mg/mL for i.p. delivery of 300 μL (60 μg per mouse or ~2 mg/Kg).
LPS doses exceeding 12 mg/Kg (~ 400 μg per mouse) have been used
in C57BL/6 inﬂammation models [21]. Donors in control groups
received matching volume i.p. injections of PBS solution. Different
groups of donors were employed for each of the three experiments
(Table 1).
2.3. Urine stimuli
Urine collection from treated donors commenced on day four posttreatment by application of abdominal pressure as previously described
[22]. Urine was collected daily for several weeks. Expressed urine from
each subject was collected in a vial and frozen until used for behavioral
assays. To attain the necessary volumes for bioassay, samples collected
from the same individual on multiple collection days were often combined. Unless otherwise speciﬁed, training trials were conducted with
urine collected 4–13 days post-treatment with RV, WNV, or LPS.
2.4. Apparatus
A Y-maze was used for biosensor training and testing as previously
described [12]. Air was conducted through two odor chambers, containing urine (0.5 mL) exposed in 35 mm Petri dishes (11 mL) to the two
arms of the maze (Table 1). Samples were randomly assigned to the
left or right odor boxes of the Y-maze. Gates were manually raised
and lowered in timed sequence to permit the training or testing of
each mouse in a session of up to 48 consecutive trials. The reward for
a correct response was a drop of water (the mouse having been restricted of water for 23 h).
2.5. Experiment 1
Experiment 1 was conducted to determine if the administration of
RV altered body odor and to investigate if this learned response was
generalized to a different vaccine treatment. For Experiment 1a, daily
training sessions consisted of pair-wise offerings of urine from individual control and RV donors and the reward was always associated with
RV-urine. Training continued daily until each biosensor achieved greater than 80% concordance (correct response to stimulus associated with
reward). Throughout training, unrewarded trials were interspersed (on
average 25% of the time) among rewarded trials.
Following training, testing sessions consisted of rewarded training
trials with interspersed unrewarded training trials (extinction) and unrewarded generalization trials (total of four per session). Experiment 1a
consisted of three different generalization experiments (Table 1). The
ﬁrst, and most important, generalizations constituted the validation experiment designed to demonstrate that the trained response was related to the vaccine treatment. Validation trials employed stimuli from the
same treatment groups as used in training sessions with the important
exception that urine samples were collected from novel individual
mouse donors (not used during training). Five sessions were completed
in the validation experiment, resulting in 78 total validation trials
among the seven biosensors. Additional generalization tests were
paired comparisons of WNV-urine versus control urine (69 trials in
four sessions) and WNV-urine versus RV-urine (59 trials in six
sessions).
Experiment 1b was conducted when it was concluded that treatment with the two vaccines resulted in similar odor alterations. Training
sessions were initiated with the Experiment 1a biosensor panel to
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directly discriminate RV-urine and WNV-urine. The water reward was
associated with urine odors from RV vaccinated mice. Because biosensors showed no evidence of discrimination between urines collected
from donors receiving the two vaccines, no generalization trials were
run in Experiment 1b.
2.6. Experiment 2
Investigation of LPS-induced odor change was conducted in two
phases to determine if LPS-trained mice could discriminate LPS- and
RV-urines in a paired comparison. In Experiment 2a, mice were trained
to discriminate between urine odor pairs from control and LPS-treated
donors collected 4–8 days post-treatment. Three biosensor mice were
rewarded for choosing the maze arm associated with LPS urine odor
and three were rewarded for association with control urine odor
(Table 1). There were six validation sessions (control versus LPS-urine
collected days 4–8 from novel donors) resulting in 69 trials. To facilitate
generalization testing with RV, a new panel of trained mice in Experiment 2b consisted of the three biosensors that had been rewarded for
selection of LPS during Experiment 2a as well as four naive subjects.
Training was similar to Experiment 2a except that all mice were
rewarded for selection of odor associated with LPS treatment. One biosensor died during Experiment 2b. The single generalization experiment (LPS-urine versus RV-urine collected on days 7 and 8) consisted
of six sessions resulting in 46 trials.
2.7. Experiment 3
The ﬁnal experiment was conducted to determine if mice trained to
recognize urine from RV-mice generalized the learned response to urine
from LPS-mice. Employing a new biosensor panel, training was conducted identically to Experiment 1a (paired comparison of RV-urine
and control urine with reward associated with RV-urine). There were
9 validation sessions (control versus RV-urine collected 4–22 days
post-treatment from novel donors) resulting in 97 trials. The other
generalization experiment (pairing control versus LPS-urine collected
4–14 days post-treatment) resulted in 56 trials in 3 sessions.
2.8. Data analysis
Correct responses for individual biosensors during training were
subjected to chi-square tests of independence. When training responses
did not differ among individuals, cumulative responses of the full panel
were calculated for training and subsequent generalization trials.
Success rates (number of correct trials divided by total trials) for speciﬁc
generalization trials were subjected to statistical tests of binomial
proportion using the continuity correction for low incidence events
[23]. No comparisons were made among generalization trial types. For
Experiment 2a, an additional test (chi-square test of independence)
was conducted to determine if training responses differed according
to the stimulus associated with the water reward (LPS or control).

differ among individual biosensors during training (p = 0.10). In validation trials, biosensors correctly chose the maze arm associated with
urine of novel RV-treated donors in 51 out of 78 (65%) unrewarded trials versus control urines (p = 0.0046; Fig. 1). In a second set of
generalization trials, biosensors trained to respond to RV vaccinetreated urine selected the maze arm associated with the urine of West
Nile virus (WNV) vaccine-treated donors in 49 out of 69 (71%) unrewarded trials versus controls (p = 0.0004) suggesting that RV and
WNV treatments result in similar volatile odor proﬁles. Biosensors
offered RV and WNV urines in direct comparisons did not discriminate
between the two different immunization types 36 out of 68 times
(53%; p = 0.36; Fig. 1).
Training trials employing direct pairing of RV-urine and WNV-urine
in Experiment 1b were not successful. No progress toward concordance
was evident after six consecutive training sessions. Whereas the novel
biosensor panel trained in Experiment 1a correctly identiﬁed RV-urine
(paired with control urine) in 62% of trials (p b 0.0001 for H0 = 50%)
after six sessions; the Experiment 1b panel identiﬁed RV-urine in only
44% of the trials when paired WNV-urine donors in rewarded trials. As
a result of this performance, the experiment was terminated.
3.2. Experiment 2
LPS-trained mice discriminated between LPS- and control mice
as well as between LPS-urine and RV-urine in paired comparisons.
The new biosensor panel discriminated LPS and control urine in
rewarded training trials (82% concordance). Response rates did not
differ among individuals during training (p = 0.15) and were not
impacted by which urine was reinforced (LPS or control) in Experiment
2a (p =0.20). In validation trials, biosensors selected the maze arm
associated with LPS urine when paired with control urine 47 out of 69
times (68%; p = 0.0019; Fig. 2). In generalization trials with RV-urine,
discrimination was observed when LPS-urine was compared with RVurine 36 out of 46 times (78%; p = 0.00011).
3.3. Experiment 3
RV-trained mice did not generalize the response to LPS-urine. Five
new biosensors were successfully trained to discriminate urine of RV
vaccine-treated donors versus controls (87% concordance). The proportion of correct responses did not differ among individual biosensors
during training (p = 0.58). In validation trials with urine of novel donors, biosensors selected the maze arm associated with urine of RV

3. Results
Following treatment, subjects receiving LPS treatment demonstrated visible indicators of sickness — i.e., lethargy and dehydration.
Reduced urinary output, while not explicitly measured, was evident
during urine collection for up to 5 or 6 days following LPS administration. No similar effects were observed among subjects treated with
the vaccines or control.
3.1. Experiment 1
Trained mice could discriminate RV-urine from control urine by
smell. Overall, biosensor concordance was 90% in rewarded training
trials in Experiment 1a. The proportion of correct responses did not

Fig. 1. Biosensor results from Experiment 1a. Mean responses are provided with 95%
conﬁdence intervals. The urine sample type associated with % response is indicated in
bold. Training trials were rewarded, while generalization trials with novel urine sources
were unrewarded. Rabies = urine of donors treated with RabVac-3® vaccine; West Nile
virus = treatment with PreveNile® vaccine; and control = treatment with phosphatebuffered saline.
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Fig. 2. Biosensor results from Experiment 2. Mean responses are provided with 95%
conﬁdence intervals. The urine sample type associated with % response is indicated in
bold. Training trials were rewarded, while generalization trials with novel urine sources
were unrewarded. Rabies = urine of donors treated with RabVac-3® vaccine;
lipopolysaccharide (LPS) = treatment with LPS solution in buffered saline; and control
= treatment with phosphate-buffered saline.

vaccinated donors in 65 out of 97 unrewarded trials (p = 0.0006;
Fig. 3). However, RV-trained mice did not discriminate between urines
of LPS-treated and control donors in generalization trials (24 out of
56; p =0.18; Fig. 3). These results suggest that volatile cues associated
with LPS treatment were different from the volatiles used by trained
biosensors to identify RV-urine.
4. Discussion
Mice were successfully trained to discriminate urines from RVtreated and control mice (Figs. 1 and 3) as well as urines from LPStreated and control mice (Fig. 2). The training response was validated
with generalization trials employing urine samples from donors that
were unfamiliar to the trained mice. The purpose of these validation trials was to exclude the possibility that individual cues, rather than treatment effects, could have been used to characterize urine samples used
during training. Information regarding the identity of samples used in
these generalization trials could be withheld from the maze operator
(thereby making her blind to the expected results) which was possible
because the generalization trials were unrewarded. Validation results
demonstrated that biosensor discrimination was made on the basis of
odors related to LPS or RV treatments, not cues learned about the
urine donors or the training paradigm.
In Experiment 1a, RV-trained biosensors generalized their response
to RV-urine by discriminating urines from WNV-treated and control donors. However, RV-trained biosensors did not discriminate RV- and
WNV-urines when presented in unrewarded head to head comparisons
(Fig. 1); neither was discrimination observed after six training sessions
with RV- and WNV-urines in Experiment 1b. Although we cannot be
certain that training with RV- and WNV-urines would not have been
successful with many additional trials, these data (along with considerable past experience with the Y-maze training paradigm) led us to
conclude that odor changes induced by these two vaccines were perceptibly very similar.
To our knowledge, these are the ﬁrst data to demonstrate that immune activation causes the expression of a distinctive odor. Because
the design of the Y-maze ensures that biosensors cannot make contact
with the odor stimuli, it is certain that the cues responsible for biosensor
discrimination are volatile compounds. Yet, the mechanisms underlying
these odor changes remain in question. Volatile metabolites may arise
at any point in the complex processes of innate or adaptive immunity.
Major histocompatibility complex (MHC) variation has been identiﬁed
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as a source of odor differences [22]. However, aspects of the current
study may exclude adaptive immunity as a source of metabolites indicative of vaccination. First, discrimination of vaccination status is apparent in as few as four days, presumably too early to implicate adaptive
immunity which occurs over several weeks. For example, peak antibody
production in humans has been observed between 14 and 28 days for
RV [24] and WNV vaccines [25]. Second, inactivated vaccines (e.g., RV)
do not participate in the cellular MHC class I pathway analogous to
live vaccines such as WNV [26]. The perceptual similarities between
RV and WNV-produced odors suggest that innate immunity processes
may be responsible for the volatile metabolites [27]. Innate immunity
triggers inﬂammation and initiates adaptive immunity via the complement system within hours of antigen presentation.
As a ﬁrst step toward examining the possible role of an innate immunity activation pathway to odor change, we examined odor changes
elicited by exposure to the potent immune activator, LPS, the prototypical bacterial endotoxin [28]. This was chosen, in part, because LPS has
been used to induce “sickness-related odors” in mice [29]. In particular,
rats exhibited avoidance behaviors of soiled bedding material collected
from conspeciﬁcs four hours after receiving 100 μg/Kg doses of LPS;
which could be blocked by the administration of anti-inﬂammatory cytokine IL-10 [29]. Validation trials in Experiment 2a indicated not only
that the biosensor response was related to treatment, but also that discrimination was possible regardless of which choice (LPS- or control
urine) was associated with the reward. Because Experiment 2b required
the biosensors to generalize their response to LPS-urine odors, a new
panel consisting of individuals reinforced to LPS-urine odor was assembled. Biosensor discrimination of LPS urine and RV urine demonstrated
that LPS and RV administration produced distinct alterations in volatile
urine metabolites (Fig. 2).
These results also suggest that the odor alterations resulting from
treatment with LPS or RV are not merely quantitatively different. If the
salient odor cues of RV-urine were quantitatively greater than the
odors resulting from LPS treatment, biosensors would have likely generalized the control response to the weaker LPS signal. Rather, they maintained the response to LPS-related odors and discriminated LPS- and
RV-urines. Likewise, biosensors would have discriminated LPS-urine
and control-urine in Experiment 3 if the odor cues of LPS-urine were
merely quantitatively greater than RV-urine odors.
A new panel was directly trained with LPS urine and control urine in
Experiment 3. Biosensors trained to discriminate RV-urine and control
urine did not generalize this response to LPS urine in Experiment 3
(Fig. 3), further indicating that these two activators of the immune

Fig. 3. Biosensor results from Experiment 3. Mean responses are provided with 95%
conﬁdence intervals. The urine sample type associated with % response is indicated in
bold. Training trials were rewarded, while generalization trials with novel urine sources
were unrewarded. Rabies = urine of donors treated with RabVac-3® vaccine;
lipopolysaccharide (LPS) = treatment with LPS solution in buffered saline; and control
= treatment with phosphate-buffered saline.
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system induced different alterations of urine odor. Although outward
indicators of acute inﬂammation (e.g., lethargy, dehydration) were
evident for subjects treated with approximately 2 mg/Kg LPS in the current study, it is unlikely that inﬂammation per se was responsible for the
differences in RV- and LPS-related odors. Peak inﬂammatory cytokine
levels in mice administered with 3 mg/Kg LPS are commonly observed
approximately four hours after treatment and return to baseline levels
after 24 h [21]. Furthermore, RV and control odors were readily discriminated by the biosensors (Fig. 1) despite the fact that inactivated viruses
(such as RV) lack the capacity to elicit potent inﬂammatory responses
[30].
Volatile cues present in urine many days after treatment with LPS or
vaccine likely represent the “memory” of an innate immunity process
that differs between these immunogens. Interaction with Toll-like
receptors (TLRs) is one example of how different classes of immunogens
may differ in innate immunity. Recognition by the innate immune system is accomplished by a number of pattern recognition receptors. For
example, cell surface recognition of LPS is accomplished by TLR4 [19].
Conversely, a variety of TLRs, RIG-I-like receptors (RLRs), and NODlike receptors (NLRs) are responsible for cytoplasmic and endosomal
recognition of viruses [31]. Discrimination between LPS- and RV-urine
odors (Fig. 2) and inability to discriminate between odors resulting
from the two vaccines (Fig. 1) are consistent with the concept that immunogens interacting with similar pattern recognition receptors elicit
similar volatile cues.
Following the detection of an immunogen, a number of innate immunity processes are initiated: antimicrobial enzymes and peptides
are released, inﬂammatory processes may be triggered, and attachment
of antigens to phagocytes is promoted. Among the biochemicals released to achieve these tasks are lipases, cytokines, and complement
protein complexes. The volatile cues detectable by trained mice may
be inﬂuenced by any or all of these cellular events. Speciﬁcally, differences between LPS and the vaccines may be related to the complement
system. Complement proteins participate in innate immunity and initiate adaptive immunity. Because complement participates in the humoral response via interactions with immunoglobulins [19], it might be
expected that the complement protein cascade responding to a bacterium (e.g., LPS) would differ from a viral response (e.g., RV or WNV). The
ﬁnding that the volatile signatures of RV and WNV vaccines are similar,
although different from LPS, may be related to this aspect of innate
immunity.
Metabolic inputs to innate immunity may be another source of
the volatiles used by the biosensors to discriminate treatments.
Using LPS and keyhole limpet hemocyanin (KLH; a very large immunogenic protein often employed in vaccines) treatments in mice, a
tradeoff between innate immunity and maximal metabolic rate was
observed — but no such cost was evident for adaptive immunity
[32]. Differences in volatiles arising from LPS treatment as compared
with the vaccines may reﬂect differences in the costs of innate responses to these immunogens. Therefore, anabolic and/or catabolic
pathways required for meeting the energy requirements of innate
immunity may themselves be the source of the volatile cues. For example, prolonged fasting produces markers indicative of amino acid
catabolism in humans, including volatile metabolites [33]. Nonvolatile metabolites of folate catabolism persist up to eleven days
in rats following administration of radio-labeled folic acid [34].
Liver functions, such as cytochrome P-450 metabolism, may also be
impacted by inﬂammation. Reduced P-450 metabolism was observed in mice 24 h after i.p. treatment with LPS [35]. In summary,
volatile cues of immunization detectable by trained mice may result
directly from immunogen recognition or response pathways; or indirectly via persistent metabolites associated with the metabolic
cost of innate immunity. Perhaps the mechanism could be further
elucidated in a series of bioassays employing urine collected from receptor knock-out transgenic mouse strains and/or donors treated directly with cytokines.

An important question raised by these studies is the potential role
that vaccination-induced odor changes may have in the context of normal social behavior of the species. Generally speaking, disease-based
odors are avoided by conspeciﬁcs [36–38] which probably functions to
limit the transmission of disease. If some or all of the odor changes indicative of disease are consequences of immune activation, one would
predict that vaccination-induced odors such as those we have studied
here may also be avoided. This hypothesis is now under investigation.
If this is so, large-scale immunization projects (e.g., to limit spread of rabies in raccoons [39]) could have unintended consequences for social
and reproductive behaviors.
In conclusion, we have demonstrated that volatile metabolites indicative of some aspect of innate immune activation are present in the
urine several days following i.p. administration of two different vaccines
or LPS. Odor differences induced by the two vaccines (RV and WNV)
were apparently imperceptible. However, it is still an open question as
to whether other vaccination-induced odors can be differentiated. This
is signiﬁcant because the more speciﬁc the odor change, the more useful
these odors could be for monitoring speciﬁc immunization status. Also,
further research is necessary to identify the metabolic pathway(s) responsible for these odor and odorant changes, their underlying chemical bases, their potential role in modifying social behavior, and their
diagnostic capabilities.
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